Skip to main content

Table 1 Demographics and baseline characteristics

From: Effects of treatment with montelukast alone, budesonide/formoterol alone and a combination of both in cough variant asthma

 

M group

(n = 33)

BF group

(n = 33)

MBF group

(n = 33)

Female, %

75.8

69.7

69.7

Age, yr

32.0 (27.5–52.0)

42.0 (33.5–51.0)

37.0 (29.0–54.5)

BMI

22.4 ± 3.2

22.7 ± 3.2

23.1 ± 3.2

Cough duration, mon

12.0 (3.8–36.3)

12.0 (4.0–40.5)

18.0 (3.5–67.0)

AR, %

50.0

57.6

51.5

Atopy, %

76.9

64.0

75.0

VAS

6.0 (5.0–7.0)

5.0 (5.0–9.0)

6.0 (5.0–8.0)

Daytime cough symptom score

2.0 (2.0–3.0)

2.0 (2.0–3.0)

2.0 (2.0–3.0)

Night-time cough symptom score

2.0 (1.0–3.0)

2.0 (1.0–3.0)

1.0 (1.0–2.0)

Log C5

1.2 (0.3–2.4)

1.8 (1.0–2.7)

1.8 (0.7–2.2)

FeNO

3.8 ± 0.6

4.1 ± 0.6

3.6 ± 0.6

Sputum Eos%

13.6 (2.0–37.6)

16.1 (4.5–31.5)

5.8 (1.3–14.5)

Blood Eos%

4.5 (2.1–7.2)

4.9 (3.3–8.4)

4.3 (3.0–7.4)

FEV1 pred%

93.3 ± 12.1

93.3 ± 12.1

94.6 ± 12.1

FEV1/FVC%

79.1 ± 8.0

78.5 ± 7.9

77.2 ± 8.0

MMEF%

64.1 ± 21.8

63.7 ± 21.5

56.3 ± 21.7

PD20

0.8 (0.3–2.4)

0.8 (0.2–2.2)

0.6 (0.2–1.8)

  1. BMI, FEV1% pred, FEV1/FVC and MMEF% pred were expressed as mean ± SD; Age, cough duration, VAS, daytime cough symptom score, night-time cough symptom score, Log C5, sputum Eos%, blood Eos% and PD20 were expressed as median (IQR); FeNO was presented as geometric mean ± SD. Female, AR, Atopy were expressed as percentage. M: montelukast alone; BF: budesonide/formoterol alone; MBF: montelukast plus budesonide/formoterol. AR: allergic rhinitis. FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; MMEF: maximal mid-expiratory flow